Cabozantinib,Nivolumab,Ipilimumab
BMS
['cabozantinib', 'nivolumab', 'ipilimumab', 'nivo', '/ipi', 'renal,(-adrenal)']
cabozantinib plus nivolumab/ipilimumab shows promise in renal cell carcinoma with variant histology #asco23 #urology #urologists #kidneycancer
The Leading News Source for Urologists - https://t.co/hDKngB4IyE
Expert clinical analysis. Practice advice. Policy perspectives.